T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary:
The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Summary:
NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Summary:
The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.
T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools
Summary:
The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.
An Anti-Viral Polypeptide: Griffithsin
Summary:
Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Summary:
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Summary:
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples
Description of Technology:
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.